New possibilities for prostate cancer treatment revealed

Researchers have identified a sub-group of cells that could contribute to prostate cancer recurrence, opening up new ways to treat the disease, which claims more than 3000 lives a year in Australia.

Published today in Science Translational Medicine, a study led by Monash University researchers has found that survive androgen withdrawal treatment. Previously unidentified, these cells are potential targets for future treatments. As they are present early in disease development, there is the possibility of therapy before the cancer reaches the aggressive, incurable stage.

Prostate cancer is the most common form of cancer in men, with around 20,000 new cases diagnosed each year in Australia.

For advanced cases, the best available treatment involves drugs that effectively mimic castration and so deprive the tumour of the that cause it to grow. Androgen deprivation therapy is highly effective; however, the tumour eventually becomes resistant to the treatment and regrows in an incurable form.

Led by Professor Gail Risbridger and Dr Renea Taylor of Monash University, researchers obtained tumour samples from 12 men with early stage, localised prostate cancer. Then, using mouse models to mimic the progression in humans, they closely observed how the cancer cells responded to and survived androgen deprivation therapy. Even after several weeks of androgen deprivation, residual continued to persist.

"The results indicate that these persistent cancer cells somehow differ from cancer cells that respond to androgen withdrawal, and are likely to be the that lead to advanced androgen-resistant disease. We will now investigate how to effectively target these cells," Professor Risbridger said.

Professor Mark Frydenberg of the Monash Department of Surgery, and Chairman of the Department of Urology, Monash Health, said ultimately the findings could lead to additional therapies to increase the effectiveness of existing prostate cancer treatments.

"This new information suggests that potentially some of the powerful targeted therapies now being used for advanced may have a role to play in earlier localised cancers, especially those with high-risk features, and this hypothesis can be actively tested," Professor Frydenberg said.

"It also allows for testing of novel new compounds to determine if these agents have effectiveness against these hormone resistant cells."

More information: "A Preclinical Xenograft Model Identifies Castration-Tolerant Cancer-Repopulating Cells in Localized Prostate Tumors," by R. Toivanen, Science Translational Medicine, 2013.

Related Stories

Effective prostate cancer treatment discovery

Feb 26, 2010

Monash University biomedical scientists have identified a new way to treat castrate resistant cells in prostate cancer sufferers - the most common cancer in Australian men.

Small molecule could have big impact on cancer

May 28, 2013

Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer.

Recommended for you

Generation of tanners see spike in deadly melanoma

10 hours ago

(AP)—Stop sunbathing and using indoor tanning beds, the acting U.S. surgeon general warned in a report released Tuesday that cites an alarming 200 percent jump in deadly melanoma cases since 1973.

Penn team makes cancer glow to improve surgical outcomes

11 hours ago

The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence.

Cancer: Tumors absorb sugar for mobility

23 hours ago

Cancer cells are gluttons. We have long known that they monopolize large amounts of sugar. More recently, it became clear that some tumor cells are also characterized by a series of features such as mobility or unlikeliness ...

User comments